These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18454052)

  • 21. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
    Perez EA; Suman VJ; Fitch TR; Mailliard JA; Ingle JN; Cole JT; Veeder MH; Flynn PJ; Walsh DJ; Addo FK
    Oncology; 2005; 69(2):117-21. PubMed ID: 16118507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
    Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
    Campone M; Blasinska-Morawiec M; Tekiela A; Koralewski P; Pouget JC; Douville I; Brandely M
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):937-43. PubMed ID: 18751706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
    Jacot W; Bibeau F; Gourgou-Bourgade S; Gutowski M; Colombo PE; Bleuse JP; Kramar A; Romieu G
    Am J Clin Oncol; 2010 Dec; 33(6):544-9. PubMed ID: 20042972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
    Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of metastatic breast cancer with vinorelbine and docetaxel.
    Savio G; Laudani A; Leonardi V; Pepe A; Scianna C; Gebbia V; Agostara B
    Am J Clin Oncol; 2006 Jun; 29(3):276-80. PubMed ID: 16755181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
    Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
    Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protracted administration of weekly docetaxel in metastatic breast cancer.
    Kuroi K; Bando H; Saji S; Toi M
    Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
    Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
    Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
    Hervonen P; Joensuu H; Joensuu T; Ginman C; McDermott R; Harmenberg U; Nyandoto P; Luukkaala T; Hemminki A; Zaitsev I; Heikkinen M; Nilsson S; Luukkaa M; Lehtinen I; Kellokumpu-Lehtinen PL
    Anticancer Res; 2012 Mar; 32(3):953-6. PubMed ID: 22399616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
    Dennison SK; Jacobs SA; Wilson JW; Seeger J; Cescon TP; Raymond JM; Geyer CE; Wolmark N; Swain SM
    Invest New Drugs; 2007 Dec; 25(6):545-51. PubMed ID: 17563856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
    ; Ikeda M; Sonoo H; Tanaka K; Kurebayashi J; Morimoto T; Tangoku A; Komaki K; Kataoka T; Ishiguro K; Yoshizawa K
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):767-71. PubMed ID: 16770094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
    Beer TM; Garzotto M; Lowe BA; Ellis WJ; Montalto MA; Lange PH; Higano CS
    Clin Cancer Res; 2004 Feb; 10(4):1306-11. PubMed ID: 14977829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
    Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
    Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
    Harvey J; Cantrell J; Campbell M; Cartmell A; Urba W; Modiano M; Schuster M; Rubin A; Newcomb T; Ghalie R
    Cancer Invest; 2001; 19(3):225-33. PubMed ID: 11338878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
    Ficorella C; Morelli MF; Ricevuto E; Cannita K; Porzio G; Baldi PL; Cianci G; DI Rocco ZC; Natoli C; Tinari N; DE Galitiis F; Calista F; Marchetti P
    Br J Cancer; 2004 Aug; 91(4):618-20. PubMed ID: 15292944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.